Sphera Funds Management LTD. lowered its holdings in Sierra Oncology Inc (NASDAQ:SRRA) by 4.9% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,022,759 shares of the biotechnology company’s stock after selling 53,047 shares during the quarter. Sphera Funds Management LTD.’s holdings in Sierra Oncology were worth $1,739,000 as of its most recent filing with the SEC.
A number of other institutional investors have also added to or reduced their stakes in the business. UBS Group AG acquired a new position in shares of Sierra Oncology during the 1st quarter worth $111,000. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Sierra Oncology by 25.5% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,950 shares of the biotechnology company’s stock worth $305,000 after buying an additional 20,950 shares during the last quarter. Bridgeway Capital Management Inc. raised its stake in shares of Sierra Oncology by 36.9% during the 3rd quarter. Bridgeway Capital Management Inc. now owns 225,000 shares of the biotechnology company’s stock worth $383,000 after buying an additional 60,700 shares during the last quarter. Spark Investment Management LLC raised its stake in shares of Sierra Oncology by 35.7% during the 2nd quarter. Spark Investment Management LLC now owns 330,900 shares of the biotechnology company’s stock worth $979,000 after buying an additional 87,100 shares during the last quarter. Finally, Acadian Asset Management LLC raised its stake in shares of Sierra Oncology by 22.4% during the 3rd quarter. Acadian Asset Management LLC now owns 386,351 shares of the biotechnology company’s stock worth $656,000 after buying an additional 70,724 shares during the last quarter. 60.50% of the stock is owned by institutional investors.
SRRA has been the subject of several research reports. Zacks Investment Research downgraded Sierra Oncology from a “hold” rating to a “sell” rating in a research note on Thursday, October 4th. ValuEngine downgraded Sierra Oncology from a “buy” rating to a “hold” rating in a research note on Tuesday, October 2nd.
Sierra Oncology (NASDAQ:SRRA) last released its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.03). On average, analysts expect that Sierra Oncology Inc will post -0.77 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This story was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this story on another site, it was stolen and republished in violation of U.S. & international copyright legislation. The legal version of this story can be read at https://www.chaffeybreeze.com/2018/12/08/sierra-oncology-inc-srra-holdings-reduced-by-sphera-funds-management-ltd.html.
Sierra Oncology Company Profile
Sierra Oncology, Inc, a clinical stage drug development company, researches, develops, and commercializes DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer.
Further Reading: Risk Tolerance and Your Investment Decisions
Want to see what other hedge funds are holding SRRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sierra Oncology Inc (NASDAQ:SRRA).
Receive News & Ratings for Sierra Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology and related companies with MarketBeat.com's FREE daily email newsletter.